VRTX vs AMGN
VRTX and AMGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | AMGNAmgen Inc. |
|---|---|---|
| Market cap | $141.70B | $251.99B |
| P/E (TTM) | 32.6 | 29.0 |
| P/B | 7.00 | 21.56 |
| P/S | 11.8x | 6.9x |
| Dividend yield | — | 2.03% |
| Revenue | $12.59B(TTM) | $38.09B(TTM) |
| Revenue growth (YoY) | 8.9% | 10.0% |
| Net income | $4.41B(TTM) | $8.74B(TTM) |
| Earnings growth (YoY) | 838.1% | 88.5% |
| EPS, diluted | $17.17(TTM) | $16.10(TTM) |
| EBIT margin | 34.8% | 24.7% |
| ROE | 19.5% | 66.0% |
| ROIC | 25.0% | 15.1% |
| 1y total return | +33.1% | +62.9% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: VRTX frente a AMGN
| Métrica | VRTX | AMGN |
|---|---|---|
| Valor final | $65.8K | $42.1K |
| Retorno total | +557.5% | +320.8% |
| CAGR | +20.0% | +14.9% |
| Volatilidad | 32.6% | 25.1% |
| Sharpe | 0.60 | 0.51 |
| Sortino | 0.88 | 0.76 |
| Caída máxima | -41.6% | -24.9% |
Basado en 2600 días de negociación comunes, 2016-06-29 → 2026-10-30 · tasa libre de riesgo 4.16% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)